Mitsumori Susumu, Tsuri Tatsuo, Honma Tsunetoshi, Hiramatsu Yoshiharu, Okada Toshihiko, Hashizume Hiroshi, Kida Shiro, Inagaki Masanao, Arimura Akinori, Yasui Kiyoshi, Asanuma Fujio, Kishino Junji, Ohtani Mitsuaki
Shionogi Research Laboratories, Shionogi & Co., Ltd., 12-4, Sagisu 5-chome, Fukushima-ku, Osaka 553-0002, Japan.
J Med Chem. 2003 Jun 5;46(12):2446-55. doi: 10.1021/jm0205189.
In an earlier paper, we reported that novel prostaglandin D(2) (PGD(2)) receptor antagonists having the bicyclo[2.2.1]heptane ring system as a prostaglandin skeleton were a potent new class of antiallergic agents and suppressed various allergic inflammatory responses such as those observed in conjunctivitis and asthma models. In the present study, we synthesized PGD(2) receptor antagonists having the 6,6-dimethylbicyclo[3.1.1]heptane ring system. These derivatives have the amide moiety, in contrast to those with the bicyclo[2.2.1]heptane ring system, which have the sulfonamide group. The derivatives having the 6,6-dimethylbicyclo[3.1.1]heptane ring also exhibited strong activity in PGD(2) receptor binding and cAMP formation assays. In in vivo assays such as allergic rhinitis, conjunctivitis, and asthma models, these series of derivatives showed excellent pharmacological profiles. In particular, compound 45 also effectively suppressed eosinophil infiltration in allergic rhinitis and asthma models. This compound (45, S-5751) is now being developed as a promising alternative antiallergic drug candidate.
在较早的一篇论文中,我们报道了以双环[2.2.1]庚烷环系统作为前列腺素骨架的新型前列腺素D₂(PGD₂)受体拮抗剂是一类强效的新型抗过敏药物,可抑制各种过敏性炎症反应,如在结膜炎和哮喘模型中观察到的那些反应。在本研究中,我们合成了具有6,6-二甲基双环[3.1.1]庚烷环系统的PGD₂受体拮抗剂。与具有双环[2.2.1]庚烷环系统且含有磺酰胺基团的那些衍生物不同,这些衍生物具有酰胺部分。具有6,6-二甲基双环[3.1.1]庚烷环的衍生物在PGD₂受体结合和环磷酸腺苷(cAMP)形成试验中也表现出强大的活性。在诸如过敏性鼻炎、结膜炎和哮喘模型等体内试验中,这一系列衍生物显示出优异的药理学特征。特别是,化合物45在过敏性鼻炎和哮喘模型中也有效抑制了嗜酸性粒细胞浸润。该化合物(45,S-5751)目前正作为一种有前景的替代性抗过敏药物候选物进行研发。